Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

In silico mutagenesis: a case study of the melanocortin 4 receptor.

Bromberg Y, Overton J, Vaisse C, Leibel RL, Rost B.

FASEB J. 2009 Sep;23(9):3059-69. doi: 10.1096/fj.08-127530. Epub 2009 May 5.

2.

Receptor-antagonist interactions in the complexes of agouti and agouti-related protein with human melanocortin 1 and 4 receptors.

Chai BX, Pogozheva ID, Lai YM, Li JY, Neubig RR, Mosberg HI, Gantz I.

Biochemistry. 2005 Mar 8;44(9):3418-31.

PMID:
15736952
4.

Molecular determinants of human melanocortin-4 receptor responsible for antagonist SHU9119 selective activity.

Yang Y, Chen M, Lai Y, Gantz I, Georgeson KE, Harmon CM.

J Biol Chem. 2002 Jun 7;277(23):20328-35. Epub 2002 Mar 23.

5.

Key amino acid residues in the melanocortin-4 receptor for nonpeptide THIQ specific binding and signaling.

Yang Y, Cai M, Chen M, Qu H, McPherson D, Hruby V, Harmon CM.

Regul Pept. 2009 Jun 5;155(1-3):46-54. doi: 10.1016/j.regpep.2009.03.006. Epub 2009 Mar 20.

6.

Contribution of the transmembrane domain 6 of melanocortin-4 receptor to peptide [Pro5, DNal (2')8]-gamma-MSH selectivity.

Chen M, Cai M, McPherson D, Hruby V, Harmon CM, Yang Y.

Biochem Pharmacol. 2009 Jan 1;77(1):114-24. doi: 10.1016/j.bcp.2008.09.023. Epub 2008 Sep 30.

7.

Novel binding motif of ACTH analogues at the melanocortin receptors.

Yang Y, Hruby VJ, Chen M, Crasto C, Cai M, Harmon CM.

Biochemistry. 2009 Oct 20;48(41):9775-84. doi: 10.1021/bi900634e.

8.

Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.

Wilczynski A, Wang XS, Joseph CG, Xiang Z, Bauzo RM, Scott JW, Sorensen NB, Shaw AM, Millard WJ, Richards NG, Haskell-Luevano C.

J Med Chem. 2004 Apr 22;47(9):2194-207.

PMID:
15084118
9.

Inhibition of melanocortin-4 receptor dimerization by substitutions in intracellular loop 2.

Piechowski CL, Rediger A, Lagemann C, Mühlhaus J, Müller A, Pratzka J, Tarnow P, Grüters A, Krude H, Kleinau G, Biebermann H.

J Mol Endocrinol. 2013 Jun 29;51(1):109-18. doi: 10.1530/JME-13-0061. Print 2013.

PMID:
23674133
10.

Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response.

Roubert P, Dubern B, Plas P, Lubrano-Berthelier C, Alihi R, Auger F, Deoliveira DB, Dong JZ, Basdevant A, Thurieau C, Clément K.

J Endocrinol. 2010 Nov;207(2):177-83. doi: 10.1677/JOE-09-0336. Epub 2010 Aug 9.

11.

Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans.

Srinivasan S, Lubrano-Berthelier C, Govaerts C, Picard F, Santiago P, Conklin BR, Vaisse C.

J Clin Invest. 2004 Oct;114(8):1158-64.

12.

Molecular determinants of ligand binding to the human melanocortin-4 receptor.

Yang YK, Fong TM, Dickinson CJ, Mao C, Li JY, Tota MR, Mosley R, Van Der Ploeg LH, Gantz I.

Biochemistry. 2000 Dec 5;39(48):14900-11.

PMID:
11101306
13.

Molecular mechanism of the intracellular segments of the melanocortin-4 receptor for NDP-MSH signaling.

Yang Y, Chen M, Loux TJ, Georgeson KE, Harmon CM.

Biochemistry. 2005 May 10;44(18):6971-9.

PMID:
15865442
14.

Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R.

Haskell-Luevano C, Hendrata S, North C, Sawyer TK, Hadley ME, Hruby VJ, Dickinson C, Gantz I.

J Med Chem. 1997 Jul 4;40(14):2133-9.

PMID:
9216831
15.

News from the protein mutability landscape.

Hecht M, Bromberg Y, Rost B.

J Mol Biol. 2013 Nov 1;425(21):3937-48. doi: 10.1016/j.jmb.2013.07.028. Epub 2013 Jul 26. Review. Erratum in: J Mol Biol. 2014 Jan 23;426(2):501.

16.

Cloning, distribution and effects of fasting status of melanocortin 4 receptor (MC4R) in Schizothorax prenanti.

Wei R, Yuan D, Zhou C, Wang T, Lin F, Chen H, Wu H, Xin Z, Yang S, Chen D, Wang Y, Liu J, Gao Y, Li Z.

Gene. 2013 Dec 10;532(1):100-7. doi: 10.1016/j.gene.2013.09.068. Epub 2013 Sep 21.

PMID:
24064145
17.

Pharmacological characterization of 40 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists and the agouti-related protein (AGRP) antagonist.

Xiang Z, Litherland SA, Sorensen NB, Proneth B, Wood MS, Shaw AM, Millard WJ, Haskell-Luevano C.

Biochemistry. 2006 Jun 13;45(23):7277-88.

PMID:
16752916
18.

The role of the DRY motif of human MC4R for receptor activation.

Yamano Y, Kamon R, Yoshimizu T, Toda Y, Oshida Y, Chaki S, Yoshioka M, Morishima I.

Biosci Biotechnol Biochem. 2004 Jun;68(6):1369-71.

19.

Molecular determination of agouti-related protein binding to human melanocortin-4 receptor.

Yang Y, Chen M, Lai Y, Gantz I, Yagmurlu A, Georgeson KE, Harmon CM.

Mol Pharmacol. 2003 Jul;64(1):94-103.

20.

Synthesis, biophysical, and pharmacological evaluation of the melanocortin agonist AST3-88: modifications of peptide backbone at Trp 7 position lead to a potent, selective, and stable ligand of the melanocortin 4 receptor (MC4R).

Singh A, Dirain ML, Wilczynski A, Chen C, Gosnell BA, Levine AS, Edison AS, Haskell-Luevano C.

ACS Chem Neurosci. 2014 Oct 15;5(10):1020-31. doi: 10.1021/cn5000953. Epub 2014 Aug 26.

Supplemental Content

Support Center